578. Cost-effectiveness of Infant Vaccination with PCV15 Compared to PCV13 in the United States

Abstract Background Streptococcus pneumoniae is a major cause of mortality and morbidity in young children. The 13-valent pneumococcal conjugate vaccine (PCV13) has been routine use children the United States (US) since 2010. An investigational 15-valent (PCV15) that protects against two additional serotypes currently under review by FDA. This study aimed to evaluate clinical economic impact infant vaccination with PCV15 compared PCV13 from US societal perspective. Methods A Markov decision-analytic model was developed estimate vs. on disease incidence, post meningitis sequalae, deaths. followed entire population over 100-year time horizon, taking herd immunity effects into account. Each program comprised 3 primary doses one booster for new birth cohorts. Model inputs were obtained published literature, online databases, unpublished data. effectiveness extrapolated observed data PCV7 trials. Costs (in 2021 USD) quality-adjusted life years (QALYs) discounted at 3% per year. Because price pediatric indication unknown, an analysis conducted determine threshold price, which defined as maximum remain cost-saving. series sensitivity analyses performed test robustness results. Results base case results projected prevented 185,711 more invasive cases, 987,727 all-cause pneumonia cases 11,151,473 acute otitis media tube-replacement PCV13. resulted expected gain 96,056 QALYs total reduction $7 billion direct medical costs (excluding costs), $4 non-medical indirect horizon. dose $28 higher than PCV13’s price. Sensitivity showed be robust plausible values key assumptions. Conclusion Infant provide both benefits cost-savings Disclosures Min Huang, PhD, Merck & Co., Inc.: full-time employee Tianyan Hu, Ph.D., full Jessica Weaver, MPH, Employee Kwame Owusu-Edusei, Elamin Elbasha, employee.